Biotech Startups

Eos SENOLYTIX develops senolytic peptides designed to restore cellular balance in aged or senescent cells across body organs, focusing on gerotherapeutics. The company targets age-related conditions through proprietary approaches to cellular rejuvenation.

1 investor

Eos BioInnovation invests in early-stage regenerative medicine therapies and technologies, focusing on cell, gene, and tissue therapies that target disease causes. The firm partners with researchers and entrepreneurs to accelerate the translation of breakthrough science into commercial biotech companies.

1 investor

Epiaxis Therapeutics develops treatments for advanced cancers.

1 investor

Epic CRISPR develops GEMS (Gene Expression Modulation System), a modular epigenetic editing platform that combines DNA-binding proteins, guide RNAs, and modulator proteins to create genetic medicines. The company serves the biotech/medtech sector with advanced tools for precise gene expression control and disease treatment.

1 investor

EpiEndo Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapies for chronic respiratory diseases such as COPD, based on research into macrolides and their effects on the lung epithelium. Its lead program, EP395 (glasmacinal), is a non-antibacterial macrolide with anti-inflammatory activity that is Phase 2b ready.

1 investor

A company bringing together expertise in genetics, pathology, medicine, and bioinformatics to develop data science and AI solutions in the healthcare field.

1 investor

Epinoma develops EpiAmp, a methyl-preserving amplification technology to analyze epigenetic changes and methylation patterns for applications in disease detection, drug development, and patient stratification. The company serves research institutions, pharmaceutical companies, and clinical diagnostic organizations in the biotech and healthcare sectors.

1 investor

Epivara is developing an injectable, permanent alternative to surgical spay and neuter procedures for mammals, intended to be administered in a single shot without anesthesia or incisions. Its products (iSpay, iNeuter, and iNeuter-S) target pets such as cats and dogs, small animals, and livestock in the meat industry to control reproduction and reduce hormone-related issues like boar taint.

1 investor

An integrated discovery platform for rapidly identifying high-quality VHH lead molecules from humanized libraries using cDNA display technology and developability assessment for drug research programs.

1 investor

EPTAM provides precision machining, plastics, and molding manufacturing services for regulated industries including medical and aerospace sectors. The company operates multiple facilities offering quality assurance and automated inspection capabilities.

1 investor

Eptiva Therapeutics develops a precision medicine approach to pain treatment, using a bioinformatic network biology platform connected to a proprietary pain landscape database that links drug targets and biological pathways to pain-related diseases. Its Personalized Analgesics platform aims to de-risk pain drug R&D and improve clinical success rates.

1 investor

eQcell is a Canadian clinical-stage regenerative medicine company developing allogeneic equine cord blood stem cells and canine adipose-derived mesenchymal stromal cells to treat conditions such as osteoarthritis and joint infections in horses and domestic animals. It aims to provide veterinarians with off-the-shelf stem cell therapeutics as an alternative to autologous treatments.

1 investor

Equigerminal provides DNA testing services for equine genetic conditions, specifically polysaccharide storage myopathy type 1 (PSSM1) in horses. The company operates a laboratory in Portugal offering genetic analysis through mail-in samples.

1 investor

1 investor

Eris Biotech develops small-molecule drugs designed to block immune suppression mechanisms, allowing the immune system to attack solid tumors; the company is initially focusing on mesothelioma treatments.

1 investor

Esco Aster provides independent technical and investor due diligence services across biotechnology, pharmaceuticals, medical technology, and related life sciences sectors. The company advises venture capital funds, family offices, universities, and other stakeholders on scientific validity, intellectual property, manufacturing, regulatory compliance, and commercial feasibility of life science investments and technologies.

1 investor

Esco Lifesciences manufactures laboratory equipment, biopharma devices, and IVF medical equipment for clinical, research, and industrial laboratories across more than 100 countries. The company operates multiple business units including Esco Scientific for laboratory equipment, Esco Medical for ART/IVF solutions, Esco Healthcare for pharma and biotech support, and Esco Aster as a CDMO offering continuous manufacturing platforms.

1 investor

1 investor

ESIM Chemicals manufactures exclusive synthesis products and chemical intermediates for the pharmaceutical and specialty chemicals industries. The company has a long operational history in Austria, with roots in nitrogen fertilizer production that evolved into fine chemicals and pharmaceutical intermediates.

1 investor

Esperance develops targeted oncology therapeutics designed to selectively kill cancer cells, including chemotherapy-resistant cells, via a proprietary Cationic Lytic Peptide (CLYP) platform, membrane-disrupting peptides, and antibody drug conjugates. The company operates from Houston, Texas near the Texas Medical Center, with MD Anderson Cancer Center as a strategic partner.

1 investor

Essential Pharma develops and delivers pharmaceutical medicines for patients in niche populations, with a focus on rare disease, CNS, ophthalmology, and gastroenterology across approximately 70 countries.

1 investor

Etcembly builds EMLy Co-pilot, an AI platform with a conversational interface that unifies biologics design workflows—including structural modeling, variant generation, and molecule optimization—into a single tool. It serves biotechs and R&D organizations working on therapeutic candidates such as antibodies (mAbs) and TCRs.

1 investor

Eternatear develops diagnostic and therapeutic products for dry eye disease, particularly targeting Meibomian Gland Dysfunction. The company is founded by experienced ophthalmology and medical device leaders with extensive track records in bringing dry eye treatments to market.

1 investor

Ethypharm is a specialty pharmaceutical company that develops and provides injectable medicines focused on Central Nervous System conditions including severe pain and addiction treatment, as well as critical care hospital injectables. The company serves patients and healthcare providers in hospital and emergency care settings.

1 investor